Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neisseria gonorrhoeae | 38 | 2025 | 237 | 7.290 |
Why?
|
| Gonorrhea | 29 | 2025 | 186 | 6.430 |
Why?
|
| Antibodies, Bacterial | 13 | 2023 | 194 | 2.700 |
Why?
|
| Lipopolysaccharides | 19 | 2025 | 644 | 2.680 |
Why?
|
| Bacterial Vaccines | 9 | 2023 | 87 | 2.650 |
Why?
|
| Cytidine Monophosphate | 3 | 2020 | 12 | 1.850 |
Why?
|
| Complement System Proteins | 10 | 2022 | 115 | 1.630 |
Why?
|
| Sialic Acids | 6 | 2020 | 39 | 1.510 |
Why?
|
| Epitopes | 7 | 2021 | 296 | 1.290 |
Why?
|
| N-Acetylneuraminic Acid | 6 | 2025 | 54 | 1.210 |
Why?
|
| Complement Factor H | 13 | 2022 | 131 | 1.100 |
Why?
|
| Antigens, Bacterial | 8 | 2023 | 207 | 1.030 |
Why?
|
| Mice, Inbred BALB C | 12 | 2021 | 894 | 1.030 |
Why?
|
| Neuraminic Acids | 2 | 2020 | 5 | 0.850 |
Why?
|
| Cytidine Monophosphate N-Acetylneuraminic Acid | 3 | 2020 | 10 | 0.850 |
Why?
|
| Complement Activation | 3 | 2021 | 50 | 0.780 |
Why?
|
| Cathelicidins | 2 | 2025 | 12 | 0.760 |
Why?
|
| Immunoglobulin G | 9 | 2022 | 467 | 0.740 |
Why?
|
| Oligosaccharides | 5 | 2020 | 59 | 0.730 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 163 | 0.710 |
Why?
|
| Sialyltransferases | 4 | 2020 | 22 | 0.700 |
Why?
|
| Peptides | 3 | 2019 | 577 | 0.690 |
Why?
|
| Bacterial Outer Membrane Proteins | 4 | 2019 | 125 | 0.680 |
Why?
|
| Bacterial Proteins | 3 | 2023 | 769 | 0.670 |
Why?
|
| Drug Resistance, Multiple | 2 | 2020 | 34 | 0.660 |
Why?
|
| Mice | 22 | 2025 | 10833 | 0.660 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2020 | 57 | 0.640 |
Why?
|
| Complement C4b-Binding Protein | 6 | 2019 | 34 | 0.620 |
Why?
|
| Serum Bactericidal Antibody Assay | 1 | 2019 | 7 | 0.620 |
Why?
|
| Animals | 30 | 2025 | 20643 | 0.610 |
Why?
|
| Antibodies, Monoclonal | 7 | 2021 | 869 | 0.570 |
Why?
|
| Histocompatibility Antigens | 2 | 2019 | 107 | 0.530 |
Why?
|
| Immunoglobulin Fc Fragments | 5 | 2020 | 46 | 0.500 |
Why?
|
| Drug Resistance, Microbial | 1 | 2015 | 48 | 0.490 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2013 | 45 | 0.420 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 58 | 0.420 |
Why?
|
| Vagina | 4 | 2023 | 85 | 0.410 |
Why?
|
| Female | 24 | 2025 | 32591 | 0.400 |
Why?
|
| Immunization, Passive | 3 | 2021 | 108 | 0.390 |
Why?
|
| Properdin | 1 | 2012 | 13 | 0.380 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2022 | 495 | 0.380 |
Why?
|
| Disease Models, Animal | 11 | 2023 | 2181 | 0.380 |
Why?
|
| Complement Pathway, Alternative | 1 | 2012 | 22 | 0.380 |
Why?
|
| Complement Pathway, Classical | 3 | 2012 | 20 | 0.360 |
Why?
|
| Porins | 8 | 2019 | 70 | 0.330 |
Why?
|
| Mice, Transgenic | 3 | 2020 | 1273 | 0.280 |
Why?
|
| Humans | 34 | 2022 | 62935 | 0.270 |
Why?
|
| Immunotherapy | 3 | 2020 | 251 | 0.270 |
Why?
|
| Chlamydia Infections | 2 | 2022 | 76 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 4 | 2025 | 3394 | 0.240 |
Why?
|
| Interferons | 1 | 2025 | 74 | 0.230 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2025 | 60 | 0.230 |
Why?
|
| Flow Cytometry | 5 | 2016 | 670 | 0.230 |
Why?
|
| Interferon Type I | 1 | 2025 | 186 | 0.210 |
Why?
|
| Neisseria meningitidis | 4 | 2011 | 81 | 0.200 |
Why?
|
| Complement C1 Inactivator Proteins | 1 | 2002 | 3 | 0.200 |
Why?
|
| alpha-Macroglobulins | 1 | 2002 | 4 | 0.190 |
Why?
|
| Blood Bactericidal Activity | 4 | 2011 | 66 | 0.190 |
Why?
|
| Healthy Volunteers | 2 | 2019 | 75 | 0.190 |
Why?
|
| Mannans | 1 | 2002 | 20 | 0.190 |
Why?
|
| Cell Division | 1 | 2023 | 451 | 0.190 |
Why?
|
| Coinfection | 1 | 2022 | 59 | 0.190 |
Why?
|
| Lectins | 1 | 2002 | 42 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 455 | 0.180 |
Why?
|
| Plants, Genetically Modified | 1 | 2020 | 23 | 0.170 |
Why?
|
| Protein Binding | 8 | 2017 | 1607 | 0.170 |
Why?
|
| Heptoses | 2 | 2018 | 9 | 0.170 |
Why?
|
| Immunoglobulin M | 1 | 2019 | 116 | 0.160 |
Why?
|
| Mice, Knockout | 2 | 2025 | 2109 | 0.160 |
Why?
|
| Molecular Sequence Data | 7 | 2011 | 1997 | 0.160 |
Why?
|
| Mass Spectrometry | 3 | 2018 | 304 | 0.150 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 40 | 0.150 |
Why?
|
| Lactose | 1 | 2018 | 11 | 0.150 |
Why?
|
| Amino Acid Sequence | 6 | 2011 | 1595 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 234 | 0.140 |
Why?
|
| Carrier Proteins | 1 | 2002 | 706 | 0.140 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 1461 | 0.140 |
Why?
|
| Blotting, Western | 2 | 2015 | 611 | 0.130 |
Why?
|
| Virulence Factors | 1 | 2017 | 85 | 0.130 |
Why?
|
| Neuraminidase | 1 | 2016 | 43 | 0.130 |
Why?
|
| Disease Transmission, Infectious | 1 | 2016 | 24 | 0.130 |
Why?
|
| Complement C4b | 2 | 2007 | 12 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2016 | 104 | 0.120 |
Why?
|
| Drug Design | 1 | 2016 | 136 | 0.120 |
Why?
|
| Genitalia, Female | 1 | 2015 | 18 | 0.120 |
Why?
|
| Bacterial Load | 1 | 2015 | 29 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2016 | 148 | 0.110 |
Why?
|
| Microbiota | 1 | 2016 | 127 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 787 | 0.110 |
Why?
|
| Virulence | 2 | 2012 | 195 | 0.100 |
Why?
|
| Bacteria | 1 | 2016 | 306 | 0.100 |
Why?
|
| Male | 9 | 2022 | 29596 | 0.100 |
Why?
|
| Th1 Cells | 1 | 2013 | 175 | 0.100 |
Why?
|
| Antibody Specificity | 1 | 2012 | 103 | 0.090 |
Why?
|
| Adult | 5 | 2018 | 16669 | 0.090 |
Why?
|
| Autoantibodies | 1 | 2011 | 182 | 0.090 |
Why?
|
| Macrophage-1 Antigen | 1 | 2010 | 31 | 0.090 |
Why?
|
| Serum | 2 | 2007 | 29 | 0.090 |
Why?
|
| Oligopeptides | 1 | 2011 | 133 | 0.090 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 227 | 0.080 |
Why?
|
| Complement Inactivator Proteins | 1 | 2008 | 9 | 0.070 |
Why?
|
| Complement C3b | 1 | 2007 | 19 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2005 | 364 | 0.070 |
Why?
|
| Tularemia | 1 | 2007 | 16 | 0.070 |
Why?
|
| Hybridomas | 1 | 2007 | 64 | 0.070 |
Why?
|
| Galactosyltransferases | 2 | 2007 | 16 | 0.070 |
Why?
|
| Mutation | 4 | 2011 | 2600 | 0.060 |
Why?
|
| Chlamydia trachomatis | 2 | 2022 | 56 | 0.060 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2011 | 503 | 0.060 |
Why?
|
| Immune Sera | 1 | 2005 | 35 | 0.060 |
Why?
|
| Defensins | 1 | 2005 | 5 | 0.060 |
Why?
|
| Urethritis | 1 | 2005 | 9 | 0.060 |
Why?
|
| Base Sequence | 2 | 2005 | 1335 | 0.060 |
Why?
|
| DNA Probes | 1 | 2005 | 35 | 0.060 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2025 | 54 | 0.060 |
Why?
|
| Microbial Viability | 2 | 2018 | 58 | 0.060 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2005 | 102 | 0.060 |
Why?
|
| DNA Primers | 1 | 2005 | 293 | 0.060 |
Why?
|
| Immune Evasion | 1 | 2025 | 69 | 0.060 |
Why?
|
| Ethanolamines | 1 | 2003 | 19 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2005 | 390 | 0.050 |
Why?
|
| Species Specificity | 3 | 2008 | 336 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2005 | 384 | 0.050 |
Why?
|
| Fimbriae Proteins | 1 | 2002 | 15 | 0.050 |
Why?
|
| Neutrophils | 1 | 2005 | 376 | 0.050 |
Why?
|
| Serum Bactericidal Test | 1 | 2002 | 3 | 0.050 |
Why?
|
| Collectins | 1 | 2002 | 4 | 0.050 |
Why?
|
| Binding Sites, Antibody | 1 | 2002 | 23 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2002 | 51 | 0.050 |
Why?
|
| Opsonin Proteins | 1 | 2002 | 31 | 0.050 |
Why?
|
| Genes, Bacterial | 1 | 2002 | 121 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2002 | 143 | 0.050 |
Why?
|
| Host-Pathogen Interactions | 2 | 2016 | 263 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 669 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 148 | 0.040 |
Why?
|
| China | 1 | 2018 | 165 | 0.040 |
Why?
|
| Pan troglodytes | 2 | 2008 | 34 | 0.030 |
Why?
|
| Neisseria | 1 | 2016 | 5 | 0.030 |
Why?
|
| Molecular Mimicry | 1 | 2016 | 32 | 0.030 |
Why?
|
| Macaca mulatta | 2 | 2008 | 250 | 0.030 |
Why?
|
| Kinetics | 1 | 2015 | 764 | 0.030 |
Why?
|
| Survival | 1 | 2011 | 12 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2011 | 35 | 0.020 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2011 | 144 | 0.020 |
Why?
|
| Cricetulus | 1 | 2010 | 100 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 147 | 0.020 |
Why?
|
| CHO Cells | 1 | 2010 | 190 | 0.020 |
Why?
|
| Cricetinae | 1 | 2010 | 368 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 864 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2020 | 5601 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 692 | 0.020 |
Why?
|
| Papio | 1 | 2008 | 15 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2007 | 28 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2008 | 153 | 0.020 |
Why?
|
| Francisella tularensis | 1 | 2007 | 22 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 27 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2007 | 131 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2007 | 60 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2007 | 149 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2007 | 199 | 0.020 |
Why?
|
| Immunization | 1 | 2007 | 133 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2008 | 411 | 0.020 |
Why?
|
| Alleles | 1 | 2007 | 448 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2005 | 13 | 0.010 |
Why?
|
| Serotyping | 1 | 2005 | 52 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2005 | 204 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2005 | 300 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 2005 | 78 | 0.010 |
Why?
|
| Urethra | 1 | 2005 | 71 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2003 | 188 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2005 | 413 | 0.010 |
Why?
|
| Amides | 1 | 2003 | 56 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2003 | 149 | 0.010 |
Why?
|
| Poly G | 1 | 2002 | 3 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2002 | 113 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 384 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2002 | 267 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 838 | 0.010 |
Why?
|
| Middle Aged | 1 | 2011 | 17407 | 0.010 |
Why?
|